Neoplasms

All Conditions

Gland and Hormone Related Diseases

Rare Diseases

Adenoma

Hyperparathyroidism

Hyperparathyroidism, Primary

Parathyroid Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Parathyroid Diseases

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Primary Hyperparathyroidism

The study aims are:

1. To compare the diagnostic performance of parathyroid four-dimensional CT (4D-CT), scintigraphy, and ultrasound in patients who underwent parathyroid surgery for primary hyperparathyroidism.
2. To compare 4D-CT, scintigraphy, and ultrasound for the ability to perform focused parathyroidectomy, and for rates of persistent hyperparathyroidism and complications from parathyroid surgery.

Methods The investigators will create a multicenter registry consisting of patients having parathyroid surgery for primary hyperparathyroidism from July 2009 to June 2016. Initial participating centers include Duke University Medical Center, University California Los Angeles (UCLA) and University of Arkansas for Medical Sciences (UAMS).

There will be no intervention in the patient's treatment or imaging. The management will be determined by the surgeon or clinician supervising the patient's care.

The registry will consist of patient data regarding basic demographics, history of prior neck/chest surgery or radiation, parathyroid imaging, biochemical evaluation, intraoperative surgical findings, parathyroid pathology, and surgical outcomes within the first 6 months (persistent disease, recurrent laryngeal nerve injury, and hypoparathyroidism). Data will be entered into REDCap with no PHI. The investigators expect to include 3000 patients in the registry (1000 from Duke).

Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism

University of California, Los Angeles

University of Arkansas

Duke University

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Nervous System Diseases

Heart and Blood Diseases

Behaviors and Mental Disorders

Respiratory Tract (Lung and Bronchial) Diseases

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Kidney Diseases

Parkinsonian Disorders

Heart Diseases

Thyroid Diseases

Dementia

Pulmonary Embolism

Embolism

Rheumatic Diseases

Collagen Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Brain Diseases

Central Nervous System Diseases

Thrombosis

Embolism and Thrombosis

Vascular Diseases

Lung Diseases

Respiratory Tract Diseases

Connective Tissue Diseases

Ganglion Cysts

Synovial Cyst

Basal Ganglia Diseases

Movement Disorders

All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.

The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.

Scintigraphy

Gilles METRARD, Dr

Monocentric study for the evaluation of a whole body CZT scintigraphy system.

Monocentric evaluation of performances and clinical interest of a whole body scintigraphic acquisition system with CZT digital detectors. Comparison of image quality and resolution of the new system compared to a reference one, on phantoms and during the acquisition of a wide variety of examinations.

Latest Imaging SPECT System Evaluation Phase 1

Rate of images obtaining a score greater than or equal to 4 in visual image quality analysis on a 5-point LIKERT scale.

Physical measurements of collimator performance on test object.

Centre Hospitalier Régional d'Orléans

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Immunomodulating Agents

Peptide-pulsed dendritic cells

Prof. C.J.A. Punt, MD, PhD

Prof. C.G. Figdor, PhD

Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have been observed. For these therapies accurate delivery to target organs is essential. Correct delivery and subsequent migration of vaccinated DCs to regional lymph nodes is of paramount importance for effective stimulation of the immune system. Currently it is not known what the best route of administration is for DC vaccines.

Using magnetically labeled DCs, we investigate the potential of MRI cell tracking to monitor DC therapy. This is investigated in stage III/IV melanoma patients in whom a regional lymph node dissection is scheduled. Autologous monocyte-derived DCs are labeled with the clinically approved superparamagnetic iron oxide (SPIO) formulation Endorem and 111In-oxine and injected either in the skin or directly in lymph nodes under ultrasound guidance. Two days after vaccination patients are monitored with scintigraphy and MR imaging. Lymph nodes are then resected. Subsequently patients receive 3 more vaccination with DCs. During and after therapy immune responses against the used melanoma peptides are monitored.

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Active Immunization of Patients With Stage III and IV Melanoma in Whom a Regional Lymph Node Dissection is Planned, With Peptide-Pulsed Dendritic Cells: Evaluation of in Vivo Immune and Clinical Response and Migration

Dutch Cancer Society

Radboud University Medical Center

C.J.A. Punt, MD, PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism	NCT02381925	Parathyroid Ade...		18 Years -	Duke University
Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism	NCT02381925	Parathyroid Ade...		18 Years -	Duke University
Latest Imaging SPECT System Evaluation Phase 1	NCT04704349	Rheumatic Disea... Neoplasms Parathyroid Dis... Pulmonary Embol... Heart Diseases Thyroid Disease... Kidney Diseases Dementia Parkinsonian Di...	Scintigraphy	18 Years -	Centre Hospitalier Régional d'Orléans
Latest Imaging SPECT System Evaluation Phase 1	NCT04704349	Rheumatic Disea... Neoplasms Parathyroid Dis... Pulmonary Embol... Heart Diseases Thyroid Disease... Kidney Diseases Dementia Parkinsonian Di...	Scintigraphy	18 Years -	Centre Hospitalier Régional d'Orléans
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection	NCT00243594	Melanoma Stage ...	Peptide-pulsed ...	18 Years - 75 Years	Radboud University Medical Center

Spots Global Cancer Trial Database for scintigraphy

Every month we try and update this database with for scintigraphy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.